Multimodal deep learning for predicting PD-L1 biomarker and clinical immunotherapy outcomes of esophageal cancer
Although the immune checkpoint inhibitors (ICIs) have demonstrated remarkable anti-tumor efficacy in solid tumors, the proportion of ESCC patients who benefit from ICIs remains limited. Current biomarkers have assisted in identifying potential responders to immunotherapy, yet they all have inherent...
Saved in:
| Main Authors: | Hui Liu, Yinpu Bai, Zhidong Wang, Shi Yin, Cheng Gong, Bin Wang |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2025-03-01
|
| Series: | Frontiers in Immunology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fimmu.2025.1540013/full |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Survival and Perioperative Outcomes After Addition of Immunotherapy to Neoadjuvant Chemoradiotherapy for the Treatment of Locally Advanced Esophageal Squamous Cell Carcinoma
by: Canjun Li, et al.
Published: (2025-04-01) -
Prognostic value of immuno-inflammatory biomarkers in esophageal squamous cell carcinoma patients receiving immunotherapy combined with chemoradiotherapy and its association with immuno-genomic landscape
by: Xingyuan Cheng, et al.
Published: (2024-12-01) -
Immunohistochemical expression of PD-L1 in esophageal carcinoma and its correlation with histopathological features
by: Tarunpreet Saini, et al.
Published: (2024-10-01) -
Efficacy and safety of PD-1/PD-L1 inhibitors as first-line treatment for esophageal squamous cell carcinoma: a systematic review and meta-analysis
by: Wei Ren, et al.
Published: (2025-03-01) -
Corrigendum: Efficacy and safety of PD-1/PD-L1 inhibitors as first-line treatment for esophageal squamous cell carcinoma: a systematic review and meta-analysis
by: Wei Ren, et al.
Published: (2025-05-01)